FOTEMUSTINE IN PATIENTS WITH RELAPSING MALIGNANT GLIOMAS - A PHASE-II TRIAL

被引：0
|
作者：
PUNT, CJA
STAMATAKIS, L
GERARD, B
机构：
[1] INST RECH INT SERV,BRUSSELS,BELGIUM
[2] CTR HOSP TIVOLI,LA LOUVIERE,BELGIUM
来源：
ONCOLOGY REPORTS | 1995年 / 2卷 / 02期
关键词：
BRAIN TUMORS; GLIOMA; ASTROCYTOMA; GLIOBLASTOMA MULTIFORME; CHEMOTHERAPY; FOTEMUSTINE;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Eleven patients with relapsing malignant glioma were treated with fotemustine chemotherapy, a new nitrosourea derivative. One partial response of 13 months duration occurred, resulting in a marked improvement of the quality of life of the patient. Seven patients had stable disease for a median duration of 5 months. Median survival from inclusion in the study was 6 months. Toxicity was mainly hematologic and manageable. We confirm that fotemustine has some activity in patients with relapsing malignant glioma.
引用
收藏
页码：307 / 308
页数：2
相关论文
共 50 条
  • [31] Fotemustine in recurrent supratentorial malignant gliomas
    Mousseau, M
    Swiercz, P
    Rougny, M
    Boutonnat, J
    Mechin, I
    Chinal, J
    Passagia, JG
    Bolla, M
    Pasquier, B
    Benabid, AL
    Schaerer, R
    DRUGS OF TODAY, 1996, 32 : 43 - 50
  • [32] THE INTEGRATION OF INTERSTITIAL IMPLANTATION INTO THE PRELIMINARY MANAGEMENT OF PATIENTS WITH MALIGNANT GLIOMAS - RESULTS OF A PHASE-II NORTHERN-CALIFORNIA-ONCOLOGY-GROUP-TRIAL
    LEIBEL, S
    GUTIN, P
    PHILLIPS, T
    WARA, W
    LEVIN, V
    HANNIGAN, J
    SILVER, P
    WEAVER, K
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1987, 10 (02): : 106 - 106
  • [33] TREATMENT OF MALIGNANT SUPRATENTORIAL GLIOMAS WITH THE ASSOCIATION OF BCNU AND TAMOXIFEN - A PHASE-II STUDY
    LAFITTE, C
    LI, YJ
    AMERI, A
    CHAUVEINC, L
    POISSON, M
    DELATTRE, JY
    NEUROLOGY, 1994, 44 (04) : A308 - A308
  • [34] DISSEMINATED MALIGNANT-MELANOMAS - PHASE-II STUDY OF THE NEW NITROSOUREA SERVIER-10036 (FOTEMUSTINE)
    KHAYAT, D
    BIZZARI, JP
    WEIL, M
    FRENAY, M
    NAMAN, H
    NAMER, M
    BANZET, P
    JACQUILLAT, C
    BULLETIN DU CANCER, 1987, 74 (06) : 706 - 706
  • [35] FOTEMUSTINE - PHASE-II PILOT-STUDY IN PATIENTS WITH METASTATIC OR REDUX SOFT SARCOMA
    SPIELMANN, M
    BERILLE, J
    KHAYAT, D
    BIZZARI, JP
    JACQUILLAT, C
    TURSZ, T
    BULLETIN DU CANCER, 1991, 78 (05) : 453 - 456
  • [36] A CONCURRENT COMBINATION OF RADIATION THERAPY-FOTEMUSTINE FOR NEWLY DIAGNOSED MALIGNANT GLIOMAS, A PHASE II STUDY
    Beauchesne, P. D.
    Carnin, C.
    Bernier, V.
    Taillandier, L.
    NEURO-ONCOLOGY, 2008, 10 (06) : 1125 - 1125
  • [37] Clinical and pharmacokinetic phase II study of fotemustine in refractory and relapsing multiple myeloma patients
    Dumontet, C
    Jaubert, J
    Sebban, C
    Bouafia, F
    Ardiet, C
    Tranchand, B
    Berger, E
    Lucas, C
    Guyotat, D
    Coiffier, B
    ANNALS OF ONCOLOGY, 2003, 14 (04) : 615 - 622
  • [38] Efficacy of fotemustine in recurrent/progressive gliomas:: A phase II study
    Laguzzi, E.
    Rudà, R.
    Trevisan, E.
    Guarneri, D.
    Mocellini, C.
    Soffietti, R.
    NEURO-ONCOLOGY, 2006, 8 (04) : 347 - 347
  • [39] A PHASE-II TRIAL OF IFOSFAMIDE MESNA WITH DOXORUBICIN FOR MALIGNANT MESOTHELIOMA
    CARMICHAEL, J
    CANTWELL, BMJ
    HARRIS, AL
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1989, 25 (05): : 911 - 912
  • [40] VINDESINE FOR METASTATIC MALIGNANT-MELANOMA - A PHASE-II TRIAL
    NELIMARK, RA
    PETERSON, BA
    VOSIKA, GJ
    CONROY, JA
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1983, 6 (05): : 561 - 564
12345